These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18283220)

  • 1. How complete are drug history profiles that are based on public drug benefit claims?
    Paterson JM; Suleiman A; Hux JE; Bell C
    Can J Clin Pharmacol; 2008; 15(1):e108-16. PubMed ID: 18283220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.
    Levy AR; O'Brien BJ; Sellors C; Grootendorst P; Willison D
    Can J Clin Pharmacol; 2003; 10(2):67-71. PubMed ID: 12879144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of population-based drug databases in Canada.
    Miller E; Blatman B; Einarson TR
    CMAJ; 1996 Jun; 154(12):1855-64. PubMed ID: 8653645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications?
    Allin S; Law MR; Laporte A
    Health Policy; 2013 May; 110(2-3):147-55. PubMed ID: 23522381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Trial" prescriptions to reduce drug wastage: results from Canadian programs and a community demonstration project.
    Paterson JM; Anderson GM
    Am J Manag Care; 2002 Feb; 8(2):151-8. PubMed ID: 11853203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability of Group Health Cooperative automated pharmacy data by drug benefit status.
    Boudreau DM; Doescher MP; Saver BG; Jackson JE; Fishman PA
    Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):877-84. PubMed ID: 15931653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of wet nebulized inhaled respiratory medications under criteria-based reimbursement guidelines in a publicly funded Seniors' Pharmacare Program in Nova Scotia, Canada.
    Bowles SK; Sketris I; Kephart G;
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):120-8. PubMed ID: 17719514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data.
    Morrato EH; Staffa JA
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):104-12. PubMed ID: 16821248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance between discharge prescriptions and insurance claims in post-myocardial infarction patients.
    Jackevicius CA; Paterson JM; Naglie G
    Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):207-15. PubMed ID: 16862605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How many "Me-Too" drugs are enough? The case of physician preferences for specific statins.
    Austin PC; Mamdani MM; Juurlink DN
    Ann Pharmacother; 2006 Jun; 40(6):1047-51. PubMed ID: 16705028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How many antibiotic prescriptions are unsubsidised in New Zealand?
    Norris P; Funke S; Becket G; Ecke D; Reiter L; Herbison P
    N Z Med J; 2006 May; 119(1233):U1951. PubMed ID: 16680168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inequity in publicly funded physician care: what is the role of private prescription drug insurance?
    Allin S; Hurley J
    Health Econ; 2009 Oct; 18(10):1218-32. PubMed ID: 19097042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the introduction of a computerized prior-authorization system on the completeness of drug exposure data.
    Gamble JM; Johnson JA; Majumdar SR; McAlister FA; Simpson SH; Eurich DT
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):551-5. PubMed ID: 23475736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of self-reported prescription drug insurance coverage.
    Grootendorst P; Newman EC; Levine MA
    Health Rep; 2003 Feb; 14(2):35-46. PubMed ID: 12658863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
    Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
    Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug coverage in Canada: who is at risk?
    Kapur V; Basu K
    Health Policy; 2005 Feb; 71(2):181-93. PubMed ID: 15607380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database.
    Bérard A; Lacasse A
    Can J Clin Pharmacol; 2009; 16(2):e360-9. PubMed ID: 19553702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using pharmacoepidemiology to inform drug coverage policy: initial lessons from a two-province collaborative.
    Paterson JM; Laupacis A; Bassett K; Anderson GM;
    Health Aff (Millwood); 2006; 25(5):1436-43. PubMed ID: 16966744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.